Journal article
Immunopharmacogenomics: Mechanisms of HLA‐Associated Drug Reactions
Clinical Pharmacology & Therapeutics, Vol.110(3), pp.607-615
2021
Abstract
The human leukocyte antigen (HLA) system is the most polymorphic in the human genome that has been associated with protection and predisposition to a broad array of infectious, autoimmune, and malignant diseases. More recently over the last two decades, HLA class I alleles have been strongly associated with T-cell-mediated drug hypersensitivity reactions. In the case of abacavir hypersensitivity and HLA-B*57:01, the 100% negative predictive value and low number needed to test to prevent a single case has led to a durable and effective global preprescription screening strategy. However, HLA associations are still undefined for most drugs clinically associated with different delayed drug hypersensitivity phenotypes, and an HLA association relevant to one population is not generalizable across ethnicities. Furthermore, while a specific risk HLA allele is necessary for drug-induced T-cell activation, it is not sufficient. The low and incomplete positive predictive value has hindered efforts at clinical implementation for many drugs but has provided the impetus to understand the mechanisms of HLA class I restricted T-cell-mediated drug hypersensitivity reactions. Current research has focused on defining the contribution of additional elements of the adaptive immune response and other genetic and ecologic risk factors that contribute to drug hypersensitivity risk. In this review we focus on new insights into immunological, pharmacological, and genetic mechanisms underpinning HLA-associated drug reactions and the implications for future translation into clinical care.
Details
- Title
- Immunopharmacogenomics: Mechanisms of HLA‐Associated Drug Reactions
- Authors/Creators
- P. Deshpande (Author/Creator) - Murdoch UniversityR.J. Hertzman (Author/Creator) - Murdoch UniversityA.M. Palubinsky (Author/Creator) - Vanderbilt UniversityJ.B. Giles (Author/Creator) - University of ArizonaJ.H. Karnes (Author/Creator) - University of ArizonaA. Gibson (Author/Creator) - Murdoch UniversityE.J. Phillips (Author/Creator) - Murdoch University
- Publication Details
- Clinical Pharmacology & Therapeutics, Vol.110(3), pp.607-615
- Publisher
- Nature Publishing Group
- Identifiers
- 991005540028407891
- Copyright
- © 2021 The Authors. Clinical Pharmacology & Therapeutics/American Society for Clinical Pharmacology and Therapeutics
- Murdoch Affiliation
- Institute for Immunology and Infectious Diseases
- Language
- English
- Resource Type
- Journal article
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites
Metrics
99 File views/ downloads
93 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- International collaboration
- Citation topics
- 1 Clinical & Life Sciences
- 1.265 Dermatology - Skin Allergies
- 1.265.1140 Drug Hypersensitivity
- Web Of Science research areas
- Pharmacology & Pharmacy
- ESI research areas
- Pharmacology & Toxicology